An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas

Item

http://www.wikidata.org/entity/Q50556522

Q50556522

about

Considerations for dosing immunoglobulin in obese patients.Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.

P2860

Q39163785-4C788035-BE92-4423-9E24-F3771DE3E261 Q42183204-9ABF58E6-8D0B-470E-AAF6-E1FBC7F86F05

P2860

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas

Item

http://www.wikidata.org/entity/Q50556522

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

An open, prospective trial inv ...... rimary immunodeficiency diseas

@en

An open, prospective trial inv ...... rimary immunodeficiency diseas

@nl

type

Item

label

An open, prospective trial inv ...... rimary immunodeficiency diseas

@en

An open, prospective trial inv ...... rimary immunodeficiency diseas

@nl

prefLabel

An open, prospective trial inv ...... rimary immunodeficiency diseas

@en

An open, prospective trial inv ...... rimary immunodeficiency diseas

@nl

P1476

An open, prospective trial inv ...... rimary immunodeficiency diseas

@en

P2093

A Salama

http://www.w3.org/2001/XMLSchema#string

A Wartenberg-Demand

http://www.w3.org/2001/XMLSchema#string

C Sonnenburg

http://www.w3.org/2001/XMLSchema#string

Ch Königs

http://www.w3.org/2001/XMLSchema#string

G Kriván

http://www.w3.org/2001/XMLSchema#string

R Linde

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)

Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.

Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.

Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.

Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Immunoglobulin treatment in primary antibody deficiency.

A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.

A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.

Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.

Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.

P304

248-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VOX.12275

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

E Bernatowska

P577

2015-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25953213

http://www.w3.org/2001/XMLSchema#string

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas

about

P2860

P2860

An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseas

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698